Whether we like it or not there is risk in ETRM right now. When we get the ADCOM visit we will go higher but the real money will come in after approval. So they have to pay up. I like the risk/reward at this price, because I can quantify my downside. On the upside I am not a seller.
IDRA is in the RNAi space...Look at ALMY and TKMR and the recent joker Dicerna..Came at 15 and went to 45...Hot space. No drugs..Great stories..may be great shorts. RNAi drugs are the modern monoclonal antibodies..years away... But look at the geniuses at SNY..Thay gave $700 MM to Alnylam..
I would like to bring your attention to the stock FURX. They just got great data on a Phase III for irritable bowel syndrome. The stock is up 130%. The market pay attention to and pays up for great Phase III data.
Dear Yankee fan. I lost one parent to the disease and three friends. Do not tell me how to be compassionate.
IS it better if I call the BIG 305? I have seen people destroyed by the chemo and #$%$ they inject into these people. Truth be told I would rather dive into a vat of Demerol than have the cures they basically kill these people with. I apologize if I seem too cold. Next time I will just use numbers. But be that as it may, you do not have to read what I write and if you do keep your opinion to yourself.
SNY talks for 121 and 398 is dead until we have 305 bodies. They will update nothing. Not gonna happen.
Find a good book to read. Next news will be a major collaboration. When? It's Mulroy at the controls. He has less credibility than Obama.
There was a .10 bid for the Feb!!!!! $2.50 calls..You buy the stock and sell the call and it is a 36% return for 19 days....Annual that puppy
You are preaching to the choir..This company has no message. As I said, MIT, Harvard, Cambridge mafia that gives itself tons of options and could care less about the shareholder. Mulroy promised deals for the last two years and we got zip. With all the drug companies running out of patent protection and having nothing in the clinic you would think our dopey management would do something. I bet you can't wait for the next financing...
This has nothing to do with ETRM...The market will buy the stock when they get the FDA meeting and big institutions will buy when it gets approved. Outside of T Rowe and a few others it is very hard to buy a stock at $2.00. You can't margin this stock so the cash specks have to sell when someone utters the words:
" Margin call gentlemen."
I am bidding for calls and they are wildy overpriced and no one wants to sell them.
Off hand I would guess hedge fund selling..MACK did not participate in the biotech run so they bail..
No news..but the company's PR machine went over a cliff...